32 ms·
Yes and no. Yes, mortality is low generally, but grows exponentially with age, so pretty high for older people (1-10+ %). And you don't have to choose death as
by Pyramus 5y ago
Yes and no. Yes, mortality is low generally, but grows exponentially with age, so pretty high for older people (1-10+ %).
And you don't have to choose death as your trial end point, you can take something else that is clinically meaningful, e.g. duration of stay in the hospital (not an expert).
What seems to make things difficult with Covid (according to a German virologist working on treatment options) is that we more and more believe Covid is a conglomerate of several different "sub-diseases" (can't remember the correct medical term), i.e. the virus can trigger qualitatively different physiological reactions in different people, and it's not clear at all why.
- bsaul 5y agoInteresting you mention old people, because one of the most striking results IHU team claimed to have with HCQ was on EPAD (old people house). Unfortunately, their trial was stopped by the health authority (probably at the time HCQ was thought to be toxic based on a now retracted fraudulent study). I know i start to sound like a zealot, but i've been followed this team's work for more than a year now, and i'm absolutely stunned their work isn't more valued, at least in their country. I'm not a health expert, but i've worked for a long enough time to feel when someone's during serious work (not to mention the fact that they've often been very informative on the virus itself, which made me less surprised by the evolution of the pandemic).